SCHEMBL1022348

SCHEMBL1022348

CNCCNc1nc(Cc2cccc(F)c2)ns1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.49
NPC1 O15118 1/20 0.42
HTR6 P50406 1/20 0.40
CARM1 Q86X55 3/20 0.38
PRMT6 Q96LA8 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
TLR8 Q9NR97 1/20 0.36
TLR7 Q9NYK1 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
HRH4 Q9H3N8 1/20 0.34
GPR84 Q9NQS5 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
SLC2A1 P11166 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CCNE2 O96020 1/20 0.34
CCNE1 P24864 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1023888 0.88 CCNT1 (0.41) TAAR1NPC1HTR6HTR2CHTR2B
SCHEMBL1021101 0.87 TAAR1 (0.42) TAAR1NPC1HTR6L3MBTL1HTR2C
SCHEMBL1023535 0.86 TAAR1 (0.39) TAAR1NPC1HTR6HTR2CHTR2B
SCHEMBL1021355 0.86 ALDH1A1 (0.43) TAAR1NPC1HTR6HTR2CHTR2B
SCHEMBL1020704 0.85 TAAR1 (0.38) TAAR1NPC1HTR6L3MBTL1HTR2C
SCHEMBL1021113 0.85 TAAR1 (0.38) TAAR1NPC1HTR6L3MBTL1HTR2C
SCHEMBL1023662 0.84 NPC1 (0.39) TAAR1NPC1HTR6L3MBTL1HTR2C
SCHEMBL1020888 0.84 TAAR1 (0.44) TAAR1NPC1HTR6HTR2CTLR8
SCHEMBL1022844 0.84 ATM (0.41) TAAR1NPC1L3MBTL1LMNAMAPT
SCHEMBL1021236 0.83 HTR6 (0.40) TAAR1NPC1HTR6L3MBTL1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP TAAR1 2621/4885NPC1 777/4885HTR6 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.